| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2025 | On business and financial situation | The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 24 Jul 2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | Download |
| 24 Jul 2025 | On P&L | The Company releases the first half 2025 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2025 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors | Download |
| 07 Jan 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2024 | Download |
| 07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download |
| 03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download |
| 12 Sep 2024 | Other relevant information | The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |